Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal.Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its…
Belite Bio’s $36 Million IPO


Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal.Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its…
…